基于体素的肿瘤剂量与肝细胞癌经动脉放射性栓塞术后完全病理坏死相关
本研究在单中心纳入2015年1月至2023年6月接受钇-90玻璃微球经动脉放射性栓塞后行肝移植的41例肝细胞癌患者,用基于体素的剂量学分析肿瘤剂量与移植病理完全坏死的关系。26例(63%)达到完全缓解,肿瘤体积95%、70%、50%剂量均与完全缓解可能性相关(均p<0.05),D95>719 Gy预测完全缓解准确率最高为68%(灵敏度58%、特异度87%)。
要点
- 完全缓解组中位D95为813 Gy,非完全缓解组为232 Gy(p<0.01)。
- D95>719 Gy预测完全缓解准确率68%,灵敏度58%、特异度87%。
- V100、V200、V300、V400中位数在完全缓解组均为100%,非完全缓解组分别为99%、97%、74%、43%(均p<0.05)。
核心结论
- 基于体素的剂量学与移植病理相关性良好。
- D95阈值的准确率最高,提示D95可能是多 compartment 剂量学的相关靶目标。
研究设计与样本
- 单中心研究,纳入2015年1月至2023年6月接受钇-90玻璃微球经动脉放射性栓塞并接受肝移植的肝细胞癌患者共41例。
- 使用Simplicity90(Mirada Medical,英国牛津)结合轫致辐射SPECT/CT确定钇-90分布和剂量-体积直方图。
- 完全缓解定义为移植病理显示完全坏死且患者TARE后未对同一肿瘤接受额外治疗。
- 采用逻辑回归和受试者工作特征(ROC)曲线评估与缓解相关的剂量阈值。
主要发现
- 26例(63%)符合完全缓解标准。
- 肿瘤体积95%(D95)、70%(D70)、50%(D50)剂量与完全缓解可能性相关(均p<0.05)。
- 完全缓解组 vs 非完全缓解组中位D95为813 Gy vs 232 Gy,D70为1052 Gy vs 315 Gy,D50为1181 Gy vs 369 Gy(均p<0.01)。
- D95>719 Gy预测完全缓解准确率最高为68%(灵敏度58%、特异度87%)。
- 完全缓解组 vs 非完全缓解组中位V100为100% vs 99%,V200为100% vs 97%,V300为100% vs 74%,V400为100% vs 43%(均p<0.05)。
关键数值与推荐
- D95>719 Gy预测完全缓解的准确率为68%,灵敏度58%,特异度87%。
- 完全缓解组中位D95为813 Gy,非完全缓解组为232 Gy(p<0.01)。
- 完全缓解组中位D70为1052 Gy,非完全缓解组为315 Gy(p<0.01)。
- 完全缓解组中位D50为1181 Gy,非完全缓解组为369 Gy(p<0.01)。
- 完全缓解组中位V100、V200、V300、V400均为100%,非完全缓解组分别为99%、97%、74%、43%(均p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The transarterial radioembolization (TARE) dose is traditionally calculated using the single-compartment Medical Internal Radiation Dose (MIRD) formula. This study utilized voxel-based dosimetry to correlate tumor dose with explant pathology in order to identify dose thresholds that predicted response. METHODS: All patients with HCC treated with TARE using yttrium-90 [90Y] glass microspheres at a single institution between January 2015 - June 2023 who underwent liver transplantation were eligible. The [90Y] distribution and dose-volume histograms were determined using Simplicity90 (Mirada Medical, Oxford UK) with a Bremsstrahlung SPECT/CT. A complete response was assigned if explant pathology showed complete necrosis and the patient had not undergone additional treatments to the same tumor after TARE. Logistic regression and receiver operator characteristic (ROC) curves were constructed to evaluate dose thresholds correlated with response. RESULTS: Forty-one patients were included. Twenty-six (63%) met criteria for complete response. Dose to 95% (D95), 70% (D70), and 50% (D50) of the tumor volume were associated with likelihood of complete response by logistic regression (all p < 0.05). For lesions with complete response versus without, the median D95 was 813 versus 232 Gy, D70 was 1052 versus 315 Gy, and D50 was 1181 versus 369 Gy (all p < 0.01). A D95 > 719 Gy had the highest accuracy at 68% (58% sensitivity, 87% specificity) for predicting complete response. Median percent of tumor volume receiving at least 100 Gy (V100), 200 Gy (V200), 300 Gy (V300), and 400 Gy (V400) also differed by pathologic response: the median V100, V200, V300, and V400 was 100% versus 99%, 100% versus 97%, 100% versus 74%, and 100% versus 43% in the complete response versus non-complete response groups, respectively (all p < 0.05). CONCLUSION: Voxel-based dosimetry was well-correlated with explant pathology. The D95 threshold had the highest accuracy, suggesting the D95 may be a relevant target for multi-compartment dosimetry.
引用
- Pianka KT, Barahman M, Minocha J, et al. Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 38913189. doi:10.1007/s00259-024-06813-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。